A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
(201)-510-0950